Signalling and putative therapeutic molecules on the regulation of synoviocyte signalling in rheumatoid arthritis

Bone Joint Res. 2021 Apr;10(4):285-297. doi: 10.1302/2046-3758.104.BJR-2020-0331.R1.

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetrical and chronic polyarthritis. Fibroblast-like synoviocytes are mainly involved in joint inflammation and cartilage and bone destruction by inflammatory cytokines and matrix-degrading enzymes in RA. Approaches that induce various cellular growth alterations of synoviocytes are considered as potential strategies for treating RA. However, since synoviocytes play a critical role in RA, the mechanism and hyperplastic modulation of synoviocytes and their motility need to be addressed. In this review, we focus on the alteration of synoviocyte signalling and cell fate provided by signalling proteins, various antioxidant molecules, enzymes, compounds, clinical candidates, to understand the pathology of the synoviocytes, and finally to achieve developed therapeutic strategies of RA. Cite this article: Bone Joint Res 2021;10(4):285-297.

Keywords: Hyperplasia; Inflammation; Joint destruction; Rheumatoid arthritis; Synoviocytes.